Expressing support for the designation of September 2018 as "Pulmonary Fibrosis Awareness Month".

Bill: 115-hres-1072
Sponsor: full_name: Rep. Paulsen, Erik [R-MN-3]
Introduced: 2018-09-20
Policy area: Health
Subjects: Cardiovascular and respiratory health

Commemorative events and holidays

Congressional tributes

Health personnel

Medical research

Social work, volunteer service, charitable organizations
Latest action: action_date: 2018-09-20
text: Referred to the House Committee on Energy and Commerce.

Summaries:
action_date: 2018-09-20
action_desc: Introduced in House
text: <p> <p>Expresses support for the designation of Pulmonary Fibrosis Awareness Month. (Pulmonary fibrosis is scarring of the lungs that causes breathing problems.)</p> </p> <p>Expresses continued support for more robust and accelerated research to develop more effective treatments for pulmonary fibrosis and to ultimately find a cure for the disease. </p> <p>Recognizes the ongoing courage and contributions of individuals with pulmonary fibrosis who participate in clinical trials.</p>Commends the dedication of those working to improve the quality of life of individuals with pulmonary fibrosis and the families of those individuals.

tv_txt: IV 115th CONGRESS 2d Session H. RES. 1072 IN THE HOUSE OF REPRESENTATIVES September 20, 2018 Mr. Paulsen (for himself and Mr. Cohen ) submitted the following resolution; which was referred to the Committee on Energy and Commerce RESOLUTION Expressing support for the designation of September 2018 as Pulmonary Fibrosis Awareness Month .

Whereas pulmonary fibrosis is a debilitating and ultimately fatal lung condition that causes progressive scarring in the lungs and has no definitive cause; Whereas as many as 200,000 individuals in the United States are known to suffer from pulmonary fibrosis, the majority of whom are aged 50 and older; Whereas the average life expectancy from the diagnosis of the idiopathic form of pulmonary fibrosis is just 2.8 years, and as many as 80 percent of idiopathic pulmonary fibrosis patients die within 5 years of diagnosis; Whereas pulmonary fibrosis takes the lives of 40,000 or more individuals in the United States each year—approximately 1 individual every 13 minutes; Whereas many patients afflicted with pulmonary fibrosis are misdiagnosed for 1 year or longer after the patients are presenting with pulmonary fibrosis symptoms; Whereas, as of July 2018, there are no confirmed biomarkers for screening and testing for pulmonary fibrosis; Whereas a cure, treatment, or drug to halt the fibrotic process in pulmonary fibrosis does not yet exist; Whereas the symptoms of pulmonary fibrosis vary from person to person and include shortness of breath, a dry cough, fatigue, weight loss, and aching muscles and joints; Whereas volunteers, researchers, caregivers, and medical professionals are working to improve the quality of life for individuals with pulmonary fibrosis and for the families of those individuals; and Whereas developing more effective treatments for pulmonary fibrosis and providing access to quality care to individuals with pulmonary fibrosis requires increased research, education, and community support services: Now, therefore, be it

That the House of Representatives— (1) supports the designation of Pulmonary Fibrosis Awareness Month ; (2) supports the goals and ideals of Pulmonary Fibrosis Awareness Month; (3) continues to support more robust and accelerated research to develop more effective treatments for pulmonary fibrosis and to ultimately find a cure for the disease; (4) recognizes the courage and contributions of individuals with pulmonary fibrosis who participate in vital clinical trials to advance the knowledge of the disease; and (5) commends the dedication of organizations, volunteers, researchers, and millions of individuals in the United States and abroad working to improve the quality of life for individuals with pulmonary fibrosis and the families of those individuals.